Short-term effects and safety of an acute increase of intraocular pressure after intravitreal bevacizumab injection on corneal endothelial cells

Table 5 Characteristics of Endothelial Cells and IOP in Patients Undergoing Intravitreal Bevacizumab Injection (mean ± SD)

	Baseline (n = 42)	After 2 min	After 5 min	After 30 min
IOP(mmHg)^a	11.48 ± 2.22	49.71 ± 10.73	37.64 ± 11.68	14.88 ± 4.77
CD(cells/mm²)^a	2605.01 ± 399.08	2604.55 ± 381.42	2637.16 ± 284.61	2623.82 ± 275.34
CV ^a	62.65 ± 32.90	89.01 ± 74.71	74.61 ± 31.14	76.81 ± 35.77
6A(%)^a	39.95 ± 10.77	36.05 ± 14.94	38.02 ± 10.95	36.81 ± 2.44
CCT(μm)^a	507.00 ± 32.54	505.12 ± 27.66	503.95 ± 30.46	513.19 ± 28.17

After after injection, IOP intraocular pressure, CD corneal density, CV coefficient of variation, 6A hexagonality, CCT central corneal thickness, Baseline before injection
^aIOP significant increased in a stepwise manner (all, p < 0.01). After 30 min, it normalized but still higher than baseline (p < 0.01). But there were no significant change in CD, CV, 6A, or CCT according to IOP over time than baseline (all, p > 0.05) by one-way repeated measures ANOVA, Bonferroni correction

ISSN: 1471-2415